A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV- An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 Â 10 7 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n ¼ 18) and placebo recipients (n ¼ 6) for Gag or Pol-specific T-cell immune responses at week 9.
The need for an effective HIV-1 prophylactic vaccine is clear. The design of a vaccine inducing neutralizing antibodies remains problematical [1] . T-cell responses are implicated in the prevention [2, 3] and control of HIV-1 infection [4] . DNA plasmids and viral vectors offer alternatives to attenuated viruses for the induction of T-cell responses, but either used alone have limited immunogenicity [5] [6] [7] . Priming immune responses with DNA and boosting with a viral vector encoding identical antigens has proved efficient for inducing T-cell responses effective in modifying infection post-challenge in mice and non-human primates [5] [6] [7] .
We conducted a single-centre, randomized, placebocontrolled, double blind, phase I trial, the primary objectives of which were to assess the safety and immunogenicity of a vaccine strategy employing a DNA prime (pHIS-HIV-B) and a recombinant fowlpox virus (rFPV-HIV-B) boost. These constructs encode complementary HIV antigens and had proved safe, highly immunogenic and effective in controlling viral challenges in mice and non-human primates [6, 8] .
The design of pHIS-HIV-B is reported elsewhere [6] . Based on pHIS-64 (Coley Pharmaceutical Group, Boston, Massachusetts, USA) it contains 65% of the HIV-1 genome including gag, pol, truncated env, tat, vpu and rev with various mutations introduced to enhance safety, humanized CpG motifs to enhance immunogenicity and a synthetic intron before HIV gene coding sequences to optimize expression. The construct synthesized to standards of good manufacturing practices (GMP) was resuspended in 0.9% saline at 1 mg/ml (Qiagen, Germany). rFPV-HIV-B, based on attenuated strain FPV-M3, expressing identical gag and pol sequences [9] , was manufactured to GMP (Virax, Melbourne, Australia), and diluted to 5 Â 10 7 plaque forming units (pfu)/ml in 0.9% saline/10% glycerol. Identical placebos for both constructs contained diluent only.
A total of 28 volunteers were screened, and 24 eligible healthy volunteers aged between 18 and 55 years, at low risk of HIV infection, in good health and who had never received active HIV vaccines were randomly assigned in a 3 : 1 ratio to receive either active vaccine or placebo. Effective contraception was mandatory. Volunteers received 1 ml pHIS-HIV-B to the dominant deltoid at weeks 0 and 4 and 1 ml rFPV-HIV-B to the nondominant deltoid at week 8. Safety and immunogenicity were assessed at vaccine visits and at weeks 9 and 12. HIV status was determined by routine serology and pro-viral DNA (Amplicor; Roche Diagnostics, Pleasanton, California, USA). Pre and post-test counselling was performed at each visit. All procedures were approved by the local Research Ethics Committee.
Co-primary immunogenicity endpoints were comparisons at week 9 of the mean change from the baseline of All volunteers received each vaccine per schedule, attending all specified visits. All participants were Caucasian, predominately male (15/24), and were well matched between groups for age (mean 39 years). Five out of six randomly assigned to placebo were women.
There were no serious adverse events. The vaccines were well tolerated, with no local, systemic adverse events or laboratory abnormalities rated greater than grade 2. No erythema or ulceration was observed at injection sites. Systemic effects were mild and non-specific. Adverse events, local or systemic, were distributed equally between the two groups.
No significant difference in immunogenicity could be demonstrated in response to pooled Gag peptides with the mean (SD) time weighted IFN-g ELIspot response at week 9 being 6 sfu/10 6 (250) and À3 sfu/10 6 (7.7) cells in the vaccine and placebo groups, respectively (P ¼ 0.28, Fig. 1a ). There was no significant difference in the number of volunteers with positive responses (4/18 versus 1/6) at week 9 (P ¼ 0.99). These results were consistent across an exhaustive range of additional ELIspot and lymphoproliferative assays (Fig. 1b) in which various forms of Gag and Pol antigen were used as stimulating antigens. An intracellular cytokine assay demonstrated that any positive responses to Gag were mediated by CD4 T cells producing both IL-2 and IFN-g (Fig. 1c) . One vaccine recipient developed a faint p24 band on Western blot by week 12. No other bands developed in any individual. Fowlpox antibodies developed in 25% of vaccine recipients by week 12.
This combination of DNA-prime, pox-virus boost induces effective CD4 and CD8 T-cell responses in animal models. Lower peak and steady state viral loads were observed after SHIVmn229 challenge in macaques [7] . However, these vaccines administered via the same route and schedule are poorly immunogenic in humans. Recent reports suggest that other DNA vaccines boosted with other pox viruses, such as MVA, delivering similar HIV antigens, are also poorly immunogenic in humans [10] . The postulated causes of this discrepancy between responses in animal models and humans include: differences in the route of administration; the relative dose-response curves determined by differences in body size; species-specific responses to DNA vaccines; and the effects of regulatory genes such as vpu and tat on antigen presentation in humans. Being smaller than humans the relative dose normalized for body weight or surface area is much larger (6-20-fold depending on the metric used) in macaques. When a dose approximately equivalent to the dose administered here is given to macaques (0.2 mg pHIS-HIV-B), it is non-immunogenic. In contrast, doses of 1 and 4.5 mg of pHIS-HIV-B induce equivalent high levels of immunogenicity in macaques, suggesting a steep dose-response curve. On this basis, doses of 5-6 mg of pHIS-HIV-B may be immunogenic in humans. Recent unpublished reports from a number of groups suggest that DNA vaccines become immunogenic in humans at this dosage range.
The results of this trial are consistent with others exploring similar strategies of DNA prime, viral vector boost to induce T-cell immunity. The next trial of these constructs should determine whether maximal doses induce consistent immune responses. Such an approach is justified given the safety profile of these vaccines.
